InDevR, Inc., is a leader in providing progressive analytical technologies that enhance and accelerate vaccine characterization and production. The company is also committed to developing next-generation diagnostic products that will enable unprecedented tracking of seasonal and emerging influenza viruses around the globe.
InDevR provides the Cypher One™ product for automated hemagglutination analysis and the VaxArray™ Influenza potency assay for rapid quantification of hemagglutinin protein, the key ingredient in flu vaccines. The company also offers a range of other microarray-related products, including the Vidia™ Microarray Imaging System. New tools in advanced stages of R&D include the FluChip-8G™, a multiplexed influenza diagnostic providing deep genotyping influenza viruses in a simple cost-effective format. All of our products support vaccine developers and manufactures by providing faster turnaround time and improved results at an affordable price. InDevR is registered as conforming to the requirements of ISO 13485:2003 for the design, development, manufacture, installation and service of assays, instrumentation and in-vitro diagnostic devices.
In 2005, InDevR purchased a majority ownership share of 2B Technologies, a leader in the field of analytical instruments for atmospheric and environmental measurements. 2B Technologies has produced and sold more than 2,000 ozone monitors and related instruments. The two companies share a facility to promote collaboration for high quality research, manufacturing, sales, and customer service.
In 2012, InDevR raised venture capital to create a new company, ViroCyt, Inc. ViroCyt is focused on expanding the commercial market for the Virus Counter technology originally developed and marketed by InDevR. The Virus Counter provides rapid quantification of viruses resulting in faster, more accurate decision-making in settings that utilize viruses to create lifesaving products, such as viral vaccine production, protein expression, antiviral drug development, and viral diagnostics. ViroCyt was acquired by Sartorius in 2016.
InDevR continues to grow its network of partners in order to expand into new markets, develop innovative technologies and applications, and collaborate with scientists for the evaluation of new products.
Due to its dedication to addressing public health issues identified as high priority for our Nation, InDevR has received the majority of its non-dilutive funding from agencies such as the National Institute of Allergy and Infectious Diseases and BARDA. Founded in 2003, InDevR is a privately held, women-owned business based in Boulder, Colorado.
View our Career Opportunities.
InDevR Quality Policy
We strive to be a global leader in breakthrough instrumentation and assays. Through continuous improvement of all processes, we ensure that InDevR products are of high quality and meet or exceed customer expectations as well as all applicable regulations, standards, and laws.
InDevR Core Values
Integrity: We will be honest and endeavor to “do the right thing” every day with every customer.
Quality: We will take pride in our work and constantly strive for excellence.
Respect: We will treat every person with the respect that each of us would want to receive.
Accountability: We will take responsibility for our products and actions.
Common Sense: We will rely on intelligence and common sense, rather than corporate dogma, to solve problems and make decisions.
Global Environment: We will strive to minimize our footprint on the planet while seeking to improve the health of its inhabitants.
- American Chemical Society
- American Association of Clinical Chemists
- American Society for Microbiology
- Colorado Bioscience Association